Advertisement

Cardiovascular Drugs and Therapy

, Volume 10, Issue 3, pp 351–360 | Cite as

Reversal of Borrelia burgdorferiassociated dilated cardiomyopathy by antibiotic treatment?

  • R. Gasser
  • F. Fruhwald
  • M. Schumacher
  • G. Seinost
  • E. Reisinger
  • B. Eber
  • A. Keplinger
  • R. Horvath
  • B. Sedaj
  • W. Klein
  • K. Pierer
Cardiomyopathy
  • 34 Downloads

Summary

It is suggested thatBorrelia burgdorferi infection could be associated with dilated cardiomyopathy (IDC). Stanek et al. were able to cultivateBorrelia burgdorferi from myocardial biopsy tissue of a patient with longstanding dilated cardiomyopathy. Here we present a study in which we examined the effect of standard antibiotic treatment on the left ventricular ejection fraction (LVEF) in patients with dilated cardiomyopathy associated withBorrelia burgdorferi infection. In this study we assessed the serum (IgG, IgM Elisa) and history of 46 IDC patients with specific regard toBorrelia burgdorferi infection (mean LVEF 30.4±1.3%, measured by cardiac catheterization and echocardiography with the length-area-volume method). All 46 patients received standard treatment for dilated cardiomyopathy: ACE inhibitors, digitalis, and diuretics. Eleven (24%) patients showed positive serology and a history ofBorrelia burgdorferi infection; nine of these also had a typical history of tick bite and erythema chronicum migrans (ECM) and/or other organ involvement, and two had no recollection of tick bite or ECM but showed otherBorrelia burgdorferi-associated disorders (neuropathy, oligoarthritis). These 11 patients withBorrelia burgdorferi infection received standard antibiotic treatment with intravenous ceftriaxone 2 g bid for 14 days. Six (55%) recovered completely and showed a normal LVEF after 6 months, three (27%) improved their LVEF, and two (18%) did not improve at all. This amounts tonine (82%) patients with recovery/improvement in the Borrelia burgdorferi group. The 35 patients who did not show positive serology or a history ofBorrelia burgdorferi infection did not receive antibiotic treatment. In thisgroup without Borrelia burgdorferi infection 12 (26%), showed recovery/improvement following the standard treatment of dilated cardiomyopathy (see earlier). Our results indicate thatBorrelia burgdorferi infection could play a decisive role in the development of dilated cardiomyopathy, especially in a geographical region such as Graz, whereBorrelia burgdorferi is endemic. While we are aware of the small number ofBorrelia burgdorferi patients in this study, we nevertheless conclude that in a remarkable number of patients with signs ofBorrelia burgdorferi infection, dilated cardiomyopathy could be reversed and LVEF improved.

Key Words

heart failure dilated cardiomyopathy antibiotic ceftriaxone Lyme borreliosis Borrelia burgdorferi 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    GillumRF. Idiopathic cardiomyopathy in the United States, 1970–1982.Am Heart J 1986; 111:752–761.PubMedCrossRefGoogle Scholar
  2. 2.
    UnverferthDV.Dilated Cardiomyopathy. Mount Kisco, NY: Futura Publishing, 1986.Google Scholar
  3. 3.
    JohnsonRA, PalaciosI. Dilated cardiomyopathies of the adult.N Engl J Med 1982;307:1051–1119.PubMedCrossRefGoogle Scholar
  4. 4.
    HorowitzLN. Arrhythmias and sudden death in cardiac failure.Curr Opin Cardiol 1988;3:357–361.CrossRefGoogle Scholar
  5. 5.
    KleinW, GoebelR, BrandtD, MaurerE. Effect of nitroglycerin on patients with left heart failure. In: LichtlenPR, EngelHJ, SchreyA, SwanHJC, eds.Nitrates III, Cardiovascular effects. Berlin: Springer, 1981:488–494.Google Scholar
  6. 6.
    DusleagJ, KleinW, EberB et al. Frequency of magnetic resonance signal abnormalities of the brain in patients aged <50 years with idiopathic dilated cardiomyopathy.Am J Cardiol 1992;69:1446–1450.PubMedCrossRefGoogle Scholar
  7. 7.
    FusterV, GershBJ, GiulianiER, TajikAJ, BrandenburgRO, FreyeR. The natural history of dilated cardiomyopathy.Am J Cardiol 1981;47:525–531.PubMedCrossRefGoogle Scholar
  8. 8.
    Report of the WHO/ISCF task force on the definition and classification of cardiomyopathies.Br Heart J 1980;44: 672–673.Google Scholar
  9. 9.
    Criteria Committee, New York Heart Association, Inc.Diseases of the Heart and Blood Vessels. Nomenclature and Criteria for Diagnosis, 6th ed. Boston: Little Brown, 1964.Google Scholar
  10. 10.
    DecGW, PalaciosIF, FallonJT et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies: Clinical features, histologic correlates and clinical outcome.N Engl J Med 1985;312:885–890.PubMedCrossRefGoogle Scholar
  11. 11.
    BurgdorferW, BarbourAG, HayesSF et al: Lyme disease: Tick borne spirochetosis?Science 1982;216:1317–1319.PubMedCrossRefGoogle Scholar
  12. 12.
    SteereAC, GrodzickiRL, KornblattAN et al. The spirochetal etiology of Lyme disease.N Engl J Med 1983;308: 733–740.PubMedCrossRefGoogle Scholar
  13. 13.
    CoxJ, KrajdenM. Cardiovascular manifestations of Lyme disease.Am Heart J 1991;122:1449–1455.PubMedCrossRefGoogle Scholar
  14. 14.
    StanekG, KleinJ, BittnerR, GlogarD. Isolation ofBorrelia burgdorferi from the myocardium of a patient with longstanding cardiomyopathy.N Engl J Med 1990;322: 249–252.PubMedCrossRefGoogle Scholar
  15. 15.
    KleinJ, StanekG, BittnerR, HolzingerC, GlogarD. Lyme borreliosis as a cause of myocarditis and heart muscle disease.Eur Heart J 1991;12(Suppl):D73-D75.Google Scholar
  16. 16.
    StanekG, KleinJ, BittnerR, GlogarD.Borrelia burgdorferi as an etiologic agent in chronic heart failure?Scand J Infect Dis 1991;777(Suppl):85–87.Google Scholar
  17. 17.
    Van derLindeMR. Lyme carditis: Clinical characteristics of 105 cases.Scand J Infect Dis 1991;77(Suppl):81–84.Google Scholar
  18. 18.
    VlaySC, DervanJP, EliasJ, KanePP, DattwylerR. Ventricular tachycardia associated with Lyme carditis.Am Heart J 1991;121:1558–1560.PubMedCrossRefGoogle Scholar
  19. 19.
    WunderlichE, GrafA, ThessG, FoelskeH. Dilated myocardial disease as sequela of chronic Lyme carditis.Z Kardiol 1990;79:599–600.PubMedGoogle Scholar
  20. 20.
    KaellAT, VolkmanDJ, GorevicPD, DattwylerRJ. Positive Lyme serology in subacute bacterial endocarditis. A study of four patients.JAMA 1990;264:2916–2918.PubMedCrossRefGoogle Scholar
  21. 21.
    McAlisterHF, KlementowicsPT, AndrewsC, FisherJD, FeldM, FurmanS. Lyme carditis: An important cause of reversible heart block.Ann Intern Med 1989;110:339–345.PubMedGoogle Scholar
  22. 22.
    HansenK, MadsenJK. Myocarditis associated with tickborneBorrelia burgdorferi infection.Lancet 1986;1: 1323–1324.PubMedCrossRefGoogle Scholar
  23. 23.
    GoodmanJL, JurkovichP, KodnerC, JohnsonRC. Persistant cardiac and urinary tract infections withBorrelia burgdorferi in experimentally infected Syrian hamsters.J Clin Microbiol 1991;29:894–896.PubMedGoogle Scholar
  24. 24.
    GasserR, DusleagJ, ReisingerE et al. Reversal by ceftriaxone of dilated cardiomyopathy associated withBorrelia burgdorferi infection in an endemic area.Eur Heart J 1992; 13(Suppl):200.Google Scholar
  25. 25.
    GasserR, DusleagJ, ReisingerE et al. Reversibility by ceftriaxone of dilated cardiomyopathy associated withBorrelia burgdorferi infection.Circulation 1992;86:1807.Google Scholar
  26. 26.
    DattwylerRJ, HalpernJJ, VolkmanDJ, LuftBJ, Treatment of late Lyme borreliosis—randomised comparison of ceftriaxone and penicillin.Lancet 1988:1:1191–1194.PubMedCrossRefGoogle Scholar
  27. 27.
    YukJH, NightingaleCH, QuintilianiR. Clinical pharmacokinetics of ceftriaxone.Clin Pharmacokinet 1989;17: 223–235.PubMedGoogle Scholar
  28. 28.
    JohnsonRC, KodnerC, RusselM. In vitro and in vivo suscepibility of the Lyme disease spirocheteBorrelia burgdorferi to four antimicrobial agents.Antimicrob Agents Chemother 1987;31:164–167.PubMedGoogle Scholar
  29. 29.
    ShapiroED. Lyme disease.Curr Opin Infect Dis 1990;3: 638–642.CrossRefGoogle Scholar
  30. 30.
    SteereAC, HutchinsonGJ, RahnDW et al. Treatment of early manifestations of Lyme disease.Ann Intern Med 1983;99:22–26.PubMedGoogle Scholar
  31. 31.
    DattwylerRJ, HalpernJJ, PassH, LuftBJ. Ceftriaxone as effective therapy in refractory Lyme disease.J Infect Dis 1987;155:1322–1325.PubMedGoogle Scholar
  32. 32.
    ChristensonVD, WhiteDH. Evaluation of four commercially available ELISA assays for the serologic diagnosis of lyme disease.J Clin Lab Anal 1991;5:340–343.PubMedCrossRefGoogle Scholar
  33. 33.
    GuerroA, QueredaC, EscuerdoR, CoboJ, MorchilloR, Marti-BeldaP. Serologic diagnosis of Lyme disease. A pending problem.Enferm Infecc Microbiol Clin 1991;9: 335–338.Google Scholar
  34. 34.
    CorpuzM, HiltonE, LardisMP, SingerC, ZolanJ. Problems in the use of serologic tests for the diagnosis of Lyme disease.Arch Intern Med 1991;151:1837–1840.PubMedCrossRefGoogle Scholar
  35. 35.
    OstrovBE, AthreyaBH. Lyme disease. Difficulties in diagnosis and management.Pediatr Clin North Am 1991;38: 535–553.PubMedGoogle Scholar
  36. 36.
    SchwanTG, SimpsonWJ. Diagnosing Lyme disease.Ann Intern Med 1991;115:577–578.PubMedGoogle Scholar
  37. 37.
    Lyme borreliosis: Detecting the great imitator.J Am Osteopath Assoc 1991;91:573–574, 577–578.Google Scholar
  38. 38.
    RahnDW, MalawistaSE. Lyme disease: Recommendations for diagnosis and treatment.Ann Intern Med 1991;114: 472–481.PubMedGoogle Scholar
  39. 39.
    SchwanTG, KarstensRH, SchrumpfME, SimpsonWJ. Changes in antigenic reactivity ofBorrelia burgdorferi, the Lyme disease spirochete, during persistent infection in mice.Can J Microbiol 1991;37:450–454.PubMedCrossRefGoogle Scholar
  40. 40.
    SahnDJ, DeMariaA, KissloJ, WeymannA. The Committee on M-Mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-mode echocardiography: Results of a survey of echocardiographic measurements.Circulation 1978;58: 1072–1075.PubMedGoogle Scholar
  41. 41.
    ErbelR, SchweizerP, LambertsH et al. Echoventriculography. A simultaneous analysis of two-dimensional echocardiography and cineventriculography.Circulation 1983;67: 205–213.PubMedGoogle Scholar
  42. 42.
    ErbelR, SchweizerP, MeyerJ, GrennerH, KrebsW, EffertS. Bestimmung der Volumina und der Ejectionsfraktion des linken Ventrikels aus dem zweidimensionalen Echoicardiogram bei Patienten mit coronarer Herzerkrankung.Z Kardiol 1980;69:52–61.PubMedGoogle Scholar
  43. 43.
    Dusleag J, Klein W, Eber B, Gasser R, Rotman B, Neurohumoral and hemodynamic data in patients with dilated cardiomyopathy; dependence upon systolic and diastolic dysfunction. 1st International Symposium on Heart Failure-Mechanism and Management, 1989, abstract book, p. 304.Google Scholar
  44. 44.
    DusleagJ, KleinW, LuhaO et al. Comparison of the left ventricular cineangiography, echocardiographic semiautomatic edge detection and 3-dimensional computer reconstruction in the assessment of left ventricular function.Eur Heart J 1992;13(Suppl):316.Google Scholar
  45. 45.
    VonPolenzHA. Lyme-Borreliose—die “neue” Zeckenbiß-krankheit. Sicherheit im öffentlichen Dienst (Zeitschrift der kommunalen und staatlichen Unfallversicherung) 1989;1: 4–6.Google Scholar
  46. 46.
    HasslerD, ZöllerL, HaudeM, HufnagelHD, SonntagHG, Lyme-borreliose in einem europäischen Endemiegebiet. Antikörperprävalenz und klinisches Spektrum.Dtsch Med Wschr 1992;117:767–774.PubMedCrossRefGoogle Scholar
  47. 47.
    BurgdorferW. Lyme borreliosis: Ten years after discovery of the etiologic agent.Borrelia burgdorferi Infection 1991; 19:257–267.Google Scholar
  48. 48.
    BrycesonADM. Clinical pathology of the Jarisch-Herxheimer reaction.J Infect Dis 1966;133:696–703.Google Scholar
  49. 49.
    PfefferMA, VaughanDE, ParisiAF, PfefferMA. Effects of left ventricular shape and captopril on exercise capacity after anterior wall acute myocardial infarction.Am J Cardiol 1989;63:1167–1172.PubMedCrossRefGoogle Scholar
  50. 50.
    Fruhwald F, Dusleag J, Klein W, et al. Reversibility of dilated cardiomyopathy by low dose oral roxithromycin in a patient with chromic Lyme-borreliosis. Vth International Congress on Lyme Borreliosis, Arlington, VA, May 1992, abstract book.Google Scholar
  51. 51.
    GasserR, DusleagJ. Oral treatment of late Lyme borreliosis with roxithromycin plus co-trimoxazole.Lancet 1990; 336:1189–1190.PubMedCrossRefGoogle Scholar
  52. 52.
    PedersenLM, Friis-MollerA. Late treatment of Lyme arthritis.Lancet 1991;337:241.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • R. Gasser
    • 1
  • F. Fruhwald
    • 1
  • M. Schumacher
    • 1
  • G. Seinost
    • 1
  • E. Reisinger
    • 1
  • B. Eber
    • 1
  • A. Keplinger
    • 1
  • R. Horvath
    • 1
  • B. Sedaj
    • 1
  • W. Klein
    • 1
  • K. Pierer
    • 2
  1. 1.The Borreliosis Study Group, Division of Cardiology, Department of MedicineUniversity of GrazGrazAustria
  2. 2.Hygiene InstituteUniversity of GrazAustria

Personalised recommendations